	US 12,226,384 B2
	Peramivir solution type inhalant and preparation method therefor
Shixi Zhang, Guangdong (CN); Yuhuan Feng, Guangdong (CN); and Dong Miao, Guangdong (CN)
Assigned to Guangzhou Nanxin Pharmaceutical Co., Ltd., Guangzhou (CN)
Filed by Guangzhou Nanxin Pharmaceutical Co., Ltd., Guangdong (CN)
Filed on Aug. 24, 2021, as Appl. No. 17/411,044.
Application 17/411,044 is a continuation of application No. PCT/CN2019/110115, filed on Oct. 9, 2019.
Claims priority of application No. 201910137099.2 (CN), filed on Feb. 25, 2019.
Prior Publication US 2021/0386697 A1, Dec. 16, 2021
Int. Cl. A61K 31/196 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01)

CPC A61K 31/196 (2013.01) [A61K 9/0078 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/26 (2013.01)]

9 Claims

1. A peramivir solution inhalant, comprising: peramivir, an osmotic pressure regulator, a pH regulator, and water, wherein concentration of peramivir is greater than 15 mg/ml; concentration of the osmotic pressure regulator is less than 8 mg/ml; pH value of the solution inhalant ranges from 5.0 to 6.0; the peramivir solution is sterilized in a non-heating manner; the osmotic pressure regulator is selected from sodium chloride or glucose; after the solution inhalant is nebulized, its mass median aerodynamic diameter (MMAD) ranges from 3 μm to 4 μm, and its fine particle fraction (FPF) ranges from 60% to 80%.